June 24, 2020 / 11:23 AM / 10 days ago

BRIEF-Karyopharm Announces Publication Of Xpovio Phase 2B Sadal Study Results In The Lancet Haematology

June 24 (Reuters) - Karyopharm Therapeutics Inc:

* KARYOPHARM ANNOUNCES PUBLICATION OF XPOVIO® (SELINEXOR) PHASE 2B SADAL STUDY RESULTS IN THE LANCET HAEMATOLOGY

* KARYOPHARM THERAPEUTICS-MARKETING AUTHORIZATION APPLICATION FOR SELINEXOR FOR RR DLBCL IS PLANNED FOR SUBMISSION TO EUROPEAN MEDICINES AGENCY IN 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below